VIVUS (STU:VIU1) Other Long-Term Liabilities : €0.00 Mil (As of Mar. 2020)

View and export this data going back to . Start your Free Trial

What is VIVUS Other Long-Term Liabilities?

VIVUS's other long-term liabilities for the quarter that ended in Mar. 2020 was €0.00 Mil.

VIVUS's quarterly other long-term liabilities declined from Sep. 2019 (€0.00 Mil) to Dec. 2019 (€-0.00 Mil) but then increased from Dec. 2019 (€-0.00 Mil) to Mar. 2020 (€0.00 Mil).

VIVUS's annual other long-term liabilities declined from Dec. 2017 (€0.28 Mil) to Dec. 2018 (€0.20 Mil) and declined from Dec. 2018 (€0.20 Mil) to Dec. 2019 (€-0.00 Mil).

VIVUS Other Long-Term Liabilities Historical Data

The historical data trend for VIVUS's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Other Long-Term Liabilities Chart

VIVUS Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Other Long-Term Liabilities

Get a 7-Day Free Trial

VIVUS Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

VIVUS Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

VIVUS Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of VIVUS's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

VIVUS (STU:VIU1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008

Website

http://www.vivus.com

VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines